| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5689315 | European Urology | 2017 | 4 Pages |
Abstract
Our study in metastatic castration-resistant prostate cancer patients treated with docetaxel chemotherapy, with or without lenalidomide, showed that patient survival was best predicted by circulating tumor cell count at the start of treatment. A rising circulating tumor cell count after three cycles of therapy predicted poor survival, while a decline predicted good survival.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Nicholas J. Vogelzang, Karim Fizazi, John M. Burke, Ronald De Wit, Joaquim Bellmunt, Thomas E. Hutson, Edward Crane, William R. Berry, Kevin Doner, John D. Hainsworth, Pawel J. Wiechno, Kejian Liu, Michelle F. Waldman, Anita Gandhi, Debora Barton,